Lenalidomide shows significant benefit for myeloma patients, phase III study suggests

Wednesday, May 9, 2012 - 22:30 in Health & Medicine

Medical researchers report significant time-to-progression benefit as well as survival benefit for patients who took maintenance doses of lenalidomide following stem-cell transplant.

Read the whole article on Science Daily

More from Science Daily

Latest Science Newsletter

Get the latest and most popular science news articles of the week in your Inbox! It's free!

Check out our next project, Biology.Net